Clearside Biomedical

Clearside Biomedical Buyback Yield

Delisted

The Buyback Yield of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 395.09 %. In the previous year, Buyback Yield was 2.78 % — a change of 14,090.82% (higher).

Buyback Yield

395.09 %

YoY

14,090.82%

Last updated:

Buyback Yield of Clearside Biomedical is 2024 395.09 % . Buyback Yield of Clearside Biomedical was 2023 2.78 % . It decreases by 14,090.82% higher compared to the previous year.

The Clearside Biomedical Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2017
152.27 USD
Jan 1, 2018
2,275.00 USD
Jan 1, 2019
389.20 USD
Jan 1, 2020
347.16 USD
Jan 1, 2021
675.57 USD
Jan 1, 2022
19.89 USD
Jan 1, 2023
2.78 USD
Jan 1, 2024
395.09 USD
The Clearside Biomedical Buyback Yield history
YEARBuyback YieldYoY
395.09 %+14,090.82%
2.78 %-86.00%
19.89 %-97.06%
675.57 %+94.60%
347.16 %-10.80%
389.20 %-82.89%
2,275.00 %+1,394.03%
152.27 %-93.68%
2,410.80 %+324.94%
567.33 %+56.63%
362.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Buyback Yield of Clearside Biomedical is 395.09 % in 2024.

Buyback Yield of Clearside Biomedical changed from 2.78 % to 395.09 %, representing a 14,090.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Buyback Yield Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Clearside Biomedical

All Key Metrics — Clearside Biomedical